Mechanistically, elevated TCP1 drives AML tumorigenesis by stabilizing oncoproteins (AML1-ETO/PLK1), while its suppression triggers proteasomal degradation of these targets. This evidence concerns the gene RUNX1 and acute myeloid leukemia.